Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : J&J's Spravato Meets Primary Phase 3 Endpoints in Imminent Suicide Risk

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2019 | 10:32am EDT

By Colin Kellaher

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Monday said a pair of Phase 3 studies of its Spravato nasal-spray treatment for depression met their primary endpoints in adults at imminent risk for suicide.

The drug maker said Spravato in addition to standard of care showed clinically meaningful and statistically significant superiority in the reduction of depressive symptoms at 24 hours after the first dose in adults with major depressive disorder who have active suicidal ideation with intent.

Janssen said the onset of effect for currently available antidepressants can take four to six weeks, while active suicidal ideation with intent constitutes a psychiatric emergency that requires immediate intervention. The company said its studies are the first global trials in this patient population, who are typically excluded from antidepressant treatment studies.

The U.S. Food and Drug Administration in March approved Spravato for patients with treatment-resistant depression, meaning they have been unable to find relief from at least two treatments.

The nasal spray is a close chemical relation to ketamine, an anesthetic that is often abused as a party drug but has been shown to have a fast-acting impact on depression symptoms.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
09/13AMGEN : Phase 3 Study of Kyprolis, Darzalex Meets Primary Endpoint
DJ
09/13“THE DAY I MET SOME OF SAVE TH : How a Program in Bangladesh Is Helping Ne..
PU
09/12JOHNSON & JOHNSON : - New Head-to-Head Phase 3 Study Data Show Ponesimod Superio..
AQ
09/12JOHNSON & JOHNSON : The Janssen Pharmaceutical Companies - New Head-to-Head Phas..
AQ
09/10JOHNSON & JOHNSON : Janssen Pharmaceutical - New Data from Esketamine Nasal Spra..
AQ
09/10JOHNSON & JOHNSON : Janssen Pharmaceutical Companies - New Data from Esketamine ..
AQ
09/09JOHNSON & JOHNSON : J&J's Spravato Meets Primary Phase 3 Endpoints in Imminent S..
DJ
09/06JOHNSON & JOHNSON : Thinking about trading options or stock in Apple, Goldman Sa..
PR
09/05JOHNSON & JOHNSON : Announces Six Winners of the Champions of Science Africa Inn..
PU
09/05JOHNSON & JOHNSON : Announces Six Winners of the Champions of Science Africa Inn..
AQ
More news
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 5 892 M
Yield 2019 2,87%
P/E ratio 2019 19,5x
P/E ratio 2020 17,2x
EV / Sales2019 4,30x
EV / Sales2020 4,04x
Capitalization 345 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 148,50  $
Last Close Price 130,78  $
Spread / Highest target 29,2%
Spread / Average Target 13,5%
Spread / Lowest Target -5,18%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.07%345 150
ROCHE HOLDING LTD.10.52%236 116
MERCK AND COMPANY8.11%211 513
PFIZER-15.44%204 151
NOVARTIS18.45%200 777
NOVO NORDISK AS14.89%118 168